Bristol Myers Squibb has raised its full-year revenue and profit forecast after reporting second-quarter results that exceeded Wall Street estimates. The strong sales of blood thinner Eliquis and newer medicines like heart medicine Camzyos and anemia treatment Reblozyl drove the company’s growth.

Financial Results

The U.S. drugmaker reported second-quarter revenue of $12.97 billion, up 6% from a year earlier and above analysts’ average estimate of $11.75 billion. Adjusted earnings were $2.04 per share, topping expectations of $1.59 per share.

The company raised its full-year revenue forecast to $49 billion to $50 billion from its previous range of $46 billion to $47.5 billion. Bristol Myers now sees adjusted 2026 earnings of $6.75 to $7.00 a share, up from its prior view of $6.05 to $6.35.

Product Performance

Reblozyl sales of $735 million topped analysts’ expectations of about $664 million. Camzyos generated $416 million versus expectations of $365 million, while cancer cell therapy Breyanzi brought in $484 million compared with Wall Street estimates of $422 million.

The company raised its Eliquis sales forecast for the year to growth of 20% to 25%, from a prior projection of 10% to 15%. Sales of Eliquis, which Bristol Myers shares with Pfizer, were $4.48 billion in the quarter, up 22% and above analysts’ estimates of $4.06 billion.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.